Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 41Prostatic Neoplasms 32Ovarian Neoplasms 23Testicular Neoplasms 18Carcinoma, Transitional Cell 16Carcinoma, Renal Cell 16Carcinoma, Non-Small-Cell Lung 15Neoplasms 13Melanoma 13Testicular Germ Cell Tumor 12Colorectal Neoplasms 12Breast Neoplasms 12Neoplasm Metastasis 10Urethral Neoplasms 9Stomach Neoplasms 9Lung Neoplasms 9Endodermal Sinus Tumor 9Teratoma 8Pancreatic Neoplasms 8Central Nervous System Neoplasms 8Carcinoma, Embryonal 8Carcinoma, Ovarian Epithelial 7Triple Negative Breast Neoplasms 6Seminoma 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Esophageal Neoplasms 5Endometrial Neoplasms 5Penile Neoplasms 4

Interventions

Gemcitabine 11pembrolizumab 8enfortumab vedotin 8Specimen Handling 8Cisplatin 8Magnetic Resonance Spectroscopy 6avelumab 5Carboplatin 5vinflunine 4Nivolumab 4atezolizumab 3Biopsy 3cabozantinib 2Standard of Care 2Ramucirumab 2Platinum 2Ipilimumab 2Immunoglobulin G 2Doxorubicin 2Docetaxel 2Disulfides 2CTLA-4 Antigen 2Bortezomib 21,2-diaminocyclohexaneplatinum II citrate 2vandetanib 1tocilizumab 1tamibarotene 1rucaparib 1relatlimab 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ureteral Neoplasms × Paclitaxel × Genitourinary × Clear all
NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Astellas Pharma Inc

Phase 3 Completed
608 enrolled 22 charts 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡